Press Releases 2016

  • Prometic initiates rolling submission of its biologics license application (“BLA”) for plasminogen with U.S. FDA

    Prometic initiates rolling submission of its biologics license application (“BLA”) for plasminogen with U.S. FDA

    The Fast Track designation allows rolling submissions of portions of the regulatory application to be submitted and reviewed by the FDA on an ongoing basis.

    Read Article
  • Press Releases 2019

    Read More
  • Prometic comments on unusual trading activity

    Prometic comments on unusual trading activity

    Responded today at the request of the Investment Industry Regulatory Organization of Canada (“IIROC”) on behalf of the Toronto Stock Exchange on recent movement in the Corporation’s share price

    Read Article
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Prometic responds to false market data report regarding insider selling

    Prometic responds to false market data report regarding insider selling

    The Corporation does not anticipate issuing any further public statement regarding any rumours or speculation in the marketplace unless required by applicable laws.

    Read Article
  • Prometic presents PBI-4050’s positive effect on diabetic patients’ kidneys at the American Society of Nephrology annual meeting

    Prometic presents PBI-4050’s positive effect on diabetic patients’ kidneys at the American Society of Nephrology annual meeting

    “We have several presentations at this year’s ASN meeting providing further substantial evidence of PBI-4050’s ability to reduce kidney and pancreatic fibrosis and preserve their respective functions”

    Read Article
  • Prometic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial

    Prometic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial

    Prometic received clearance by Health Canada to commence a placebo-controlled phase 2 clinical trial with PBI-4050 in patients with metabolic syndrome and type 2 diabetes.

    Read Article
  • Prometic’s PBI-4050 demonstrates early evidence of efficacy in its Idiopathic Pulmonary Fibrosis (“IPF”) phase 2 clinical trial

    Prometic’s PBI-4050 demonstrates early evidence of efficacy in its Idiopathic Pulmonary Fibrosis (“IPF”) phase 2 clinical trial

    Early evidence of efficacy of PBI-4050 alone and shown to be very well tolerated whether used alone or in combination with nintedanib or pirfenidone

    Read Article
  • Prometic reports third quarter 2016 highlights and financial results

    Prometic reports third quarter 2016 highlights and financial results

    Plasminogen pivotal clinical trial results performed at 100% response rate meeting primary and secondary end points in plasminogen deficient patients

    Read Article
  • Prometic’s PBI-4050 shown to reduce pulmonary hypertension, lung remodeling and to improve right ventricular function in heart failure

    Prometic’s PBI-4050 shown to reduce pulmonary hypertension, lung remodeling and to improve right ventricular function in heart failure

    New data from research conducted at the Montreal Heart Institute presented at the American Heart Association Annual Meeting in New Orleans

    Read Article
  • Prometic to report its third quarter 2016 financial results and hold conference call webcast

    Prometic to report its third quarter 2016 financial results and hold conference call webcast

    Prometic will report its financial results for the third quarter ended September 30, 2016 on Monday November 14, 2016 after market close.

    Read Article
  • Prometic announces closing of Telesta Therapeutics Inc. acquisition

    Prometic announces closing of Telesta Therapeutics Inc. acquisition

    Provides the opportunity for further integration of manufacturing capability and capacity expansion in a 150,000 sq. ft. facility in Belleville, Ontario

    Read Article
  • Prometic’s Plasminogen meets primary and secondary end points in pivotal phase 2/3 trial

    Prometic’s Plasminogen meets primary and secondary end points in pivotal phase 2/3 trial

    Prometic reports 100% success rate on meeting clinical trial’s primary end points required for Accelerated Approval Regulatory Pathway

    Read Article
  • Prometic’s PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes phase 2 clinical trial

    Prometic’s PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes phase 2 clinical trial

    Clinically and statistically significant reduction of glycated hemoglobin (“HbA1c”) originally observed at 12 weeks is maintained at 24 weeks of treatment

    Read Article
  • Prometic’s PBI-4050 significantly reduces liver fibrosis in patients with Alström Syndrome

    Prometic’s PBI-4050 significantly reduces liver fibrosis in patients with Alström Syndrome

    Alström syndrome clinical program to be expanded to include further sites throughout Europe and North America

    Read Article
  • Prometic announces the addition of Tympanic Membrane Perforations (TMPS) to its Plasminogen’s targeted indications

    Prometic announces the addition of Tympanic Membrane Perforations (TMPS) to its Plasminogen’s targeted indications

    ProMetic expects to file its clinical trial application (“CTA”) in Q4 2016 and to initiate the clinical trial in Sweden in patients suffering from chronic tympanic membrane perforations in H1 2017

    Read Article
  • Prometic announces agreement to acquire Telesta Therapeutics Inc. In all share transaction

    Prometic announces agreement to acquire Telesta Therapeutics Inc. In all share transaction

    Under the terms of the Agreement, ProMetic will acquire all of the share capital of Telesta at a share price of $0.14 payable in ProMetic common shares.

    Read Article
  • Prometic reports second quarter 2016 highlights and financial results

    Prometic reports second quarter 2016 highlights and financial results

    H1 2016 revenues of $8.5 million vs. $4.8 million for H1 2015 and strengthened balance sheet with closing of $60.1 million bought deal equity financing

    Read Article
  • Prometic completes patients’ enrolment in pivotal plasminogen phase 2/3 clinical trial

    Prometic completes patients’ enrolment in pivotal plasminogen phase 2/3 clinical trial

    The FDA has agreed to an accelerated regulatory approval pathway, given the rarity of the condition and the related unmet medical need.

    Read Article
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Prometic completes adult patients’ enrolment in pivotal IVIG phase 3 clinical trial

    Prometic completes adult patients’ enrolment in pivotal IVIG phase 3 clinical trial

    ProMetic well positioned to become first Canadian provider of locally manufactured IVIG to serve rapidly growing Canadian market

    Read Article
  • Prometic to report its second quarter 2016 financial results and hold conference call webcast

    Prometic to report its second quarter 2016 financial results and hold conference call webcast

    ProMetic announced today that it will report its financial results for the second quarter ended June 30, 2016 on Thursday August 11, 2016 after market close.

    Read Article
  • Prometic’s plasminogen granted fast track designation by the US FDA

    Prometic’s plasminogen granted fast track designation by the US FDA

    To gain Fast Track designation, Plasminogen therapy demonstrated a strong rationale for its use as a treatment for a serious, often morbid and potentially fatal, condition.

    Read Article
  • loading
    Loading More...